Synced daily from ClinicalTrials.gov via AACT. Last sync: .
8 Empasiprubart IV clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including AChR-Ab Seropositive Generalized Myasthenia Gravis & Chronic Inflammatory Demyelinating Polyneuropathy) and 865 total planned enrollment. 3 Phase 3 Empasiprubart IV trials and 2 Phase 2 are listed. 6 Empasiprubart IV clinical trials are actively recruiting at 37 U.S. sites across 12 states. Most recent activity: NCT07091630 (Jan 2031).
Where to Participate: All Empasiprubart IV Trial Sites in the U.S. (37 sites across 12 states)
Every actively recruiting Empasiprubart IVtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
IVA Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
P2
active not recruiting
3
argenx
Aug 2024
Empasiprubart IV clinical trials: frequently asked questions
How many Empasiprubart IV clinical trials are there?
8 Empasiprubart IV clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants.
Are Empasiprubart IV clinical trials recruiting in 2026?
Yes — 5 Empasiprubart IV trials are actively recruiting in 2026, with 37 U.S. sites across 12 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Empasiprubart IV being studied for?
Empasiprubart IV is being studied for AChR-Ab Seropositive Generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), gMG and 10 more. The trials are grouped by indication on this page.
What phase is Empasiprubart IV in?
Empasiprubart IV clinical trials span 3 Phase 3, 2 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Empasiprubart IV clinical trials?
The lead sponsor across the most Empasiprubart IV trials is argenx. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Empasiprubart IVas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.